Soleno Therapeutics SLNO 深 沪
等待开盘 08-17 09:30:00 美东时间
53.01
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 53.01
- 总市值 276.29万
- 52周最高 90.3199
- 市盈率 静 135.61
- 换手率 0.00%
- 52周最低 29.43
- 委 比 0.00%
- 总股本 5.21万
- 历史最高 90.3199
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.81
- 每 手 1
- 风险率 11.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neurocrine slips as safety issues linked to Vykat XR resurface
Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added with its acquisition of Soleno Therapeu...
08-12 19:29
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
Cantor Fitzgerald Suspends Neutral Rating on Soleno Therapeutics
Cantor Fitzgerald suspends Neutral rating on Soleno Therapeutics (NASDAQ:SLNO).
05-19 20:58
Soleno Therapeutics Completes Merger and Delists from Nasdaq
The latest update is out from Soleno Therapeutics ( ($SLNO) ). On May 18, 2026,...
05-18 21:58
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong earl...
05-18 20:46
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
财报速睇 | Soleno Therapeutics 2026财年Q1营收0.95亿美元，同比增长100.0%；归母净利润0.31亿美元，扭亏为盈
华盛资讯5月8日讯，Soleno Therapeutics公布2026财年Q1业绩，公司Q1营收0.95亿美元，同比增长100.0%，归母净利润0.31亿美元，扭亏为盈。
05-08 08:02
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
